2022
STING agonist delivery by tumour-penetrating PEG-lipid nanodiscs primes robust anticancer immunity
Dane E, Belessiotis-Richards A, Backlund C, Wang J, Hidaka K, Milling L, Bhagchandani S, Melo M, Wu S, Li N, Donahue N, Ni K, Ma L, Okaniwa M, Stevens M, Alexander-Katz A, Irvine D. STING agonist delivery by tumour-penetrating PEG-lipid nanodiscs primes robust anticancer immunity. Nature Materials 2022, 21: 710-720. PMID: 35606429, PMCID: PMC9156412, DOI: 10.1038/s41563-022-01251-z.Peer-Reviewed Original ResearchConceptsSTING agonistsRobust T cell activationInnate immune stimulatorsT cell activationTumor rechallengeAnticancer immunityDendritic cellsAgonist deliverySingle doseCyclic dinucleotidesTumor antigensImmune stimulatorImmune memorySolid tumorsEnhanced immunotherapySystemic deliveryTumorsTumor cellsCancer cellsAgonistsImmunityDeliveryCellsActivationCleavable linker
2018
Towards an arthritis flare-responsive drug delivery system
Joshi N, Yan J, Levy S, Bhagchandani S, Slaughter K, Sherman N, Amirault J, Wang Y, Riegel L, He X, Rui T, Valic M, Vemula P, Miranda O, Levy O, Gravallese E, Aliprantis A, Ermann J, Karp J. Towards an arthritis flare-responsive drug delivery system. Nature Communications 2018, 9: 1275. PMID: 29615615, PMCID: PMC5882944, DOI: 10.1038/s41467-018-03691-1.Peer-Reviewed Original ResearchConceptsTriamcinolone acetonideInflammatory arthritisArthritis activityFree triamcinolone acetonideIA therapyArthritic miceRheumatoid arthritisArthritis flaresLocal drug delivery methodSingle doseDrug delivery methodsSynovial fluidDrug delivery approachEquivalent doseLocal deliveryArthritisDoseDelivery approachDrug delivery systemsTreatmentDelivery methodsDelivery systemPatientsTherapyIA severity